A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

October 5, 2024

Study Completion Date

October 5, 2024

Conditions
Healthy Participants
Interventions
DRUG

AZD6793

Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.

DRUG

Itraconazole

Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.

DRUG

AZD6793+ Itraconazole

Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.

Trial Locations (1)

14050

Research Site, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06494644 - A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants. | Biotech Hunter | Biotech Hunter